Hour24 News
Sophisticated and simple
-
Introduction Targeted radionuclide therapy with Lutetium-177 labelled PSMA (177Lu-PSMA) has emerged as a leading option for metastatic castration-resistant prostate cancer (mCRPC). Traditional dosimetry often relies…
